Picton Mahoney Asset Management Boosts Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Picton Mahoney Asset Management raised its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 57,720 shares of the medical equipment provider’s stock after purchasing an additional 134 shares during the quarter. Intuitive Surgical accounts for 0.5% of Picton Mahoney Asset Management’s investment portfolio, making the stock its 23rd largest position. Picton Mahoney Asset Management’s holdings in Intuitive Surgical were worth $19,472,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Baystate Wealth Management LLC grew its holdings in Intuitive Surgical by 150.0% during the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 45 shares during the period. MCF Advisors LLC increased its holdings in Intuitive Surgical by 108.1% in the 4th quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 40 shares during the last quarter. Atticus Wealth Management LLC increased its holdings in Intuitive Surgical by 85.4% in the 4th quarter. Atticus Wealth Management LLC now owns 89 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 41 shares during the last quarter. MeadowBrook Investment Advisors LLC bought a new stake in Intuitive Surgical in the 4th quarter valued at about $30,000. Finally, OFI Invest Asset Management purchased a new stake in Intuitive Surgical during the third quarter valued at about $25,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ISRG. BTIG Research boosted their price target on shares of Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a research report on Friday, April 19th. Piper Sandler boosted their target price on shares of Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a report on Friday, April 19th. Jefferies Financial Group raised their price target on Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a report on Friday, April 19th. Citigroup boosted their price objective on Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Finally, Mizuho increased their price objective on Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a report on Thursday, January 25th. Five analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, Intuitive Surgical currently has an average rating of “Moderate Buy” and an average price target of $396.17.

Insider Buying and Selling

In other news, Director Mark J. Rubash sold 1,709 shares of the business’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $380.00, for a total value of $649,420.00. Following the completion of the sale, the director now directly owns 16,051 shares in the company, valued at approximately $6,099,380. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, VP Marshall Mohr sold 108,790 shares of the business’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total value of $41,892,853.20. Following the completion of the sale, the vice president now owns 26,877 shares of the company’s stock, valued at approximately $10,349,795.16. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Mark J. Rubash sold 1,709 shares of the firm’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $380.00, for a total value of $649,420.00. Following the transaction, the director now owns 16,051 shares in the company, valued at $6,099,380. The disclosure for this sale can be found here. Insiders sold 228,637 shares of company stock worth $88,483,248 in the last quarter. 0.80% of the stock is owned by insiders.

Intuitive Surgical Price Performance

ISRG stock traded up $5.60 during midday trading on Tuesday, reaching $388.65. The company had a trading volume of 932,774 shares, compared to its average volume of 1,608,281. The firm has a 50-day moving average price of $385.34 and a 200-day moving average price of $351.97. The company has a market capitalization of $137.86 billion, a P/E ratio of 70.15, a P/E/G ratio of 4.93 and a beta of 1.39. Intuitive Surgical, Inc. has a 1 year low of $254.85 and a 1 year high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.10. The company had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.00 earnings per share. On average, equities analysts predict that Intuitive Surgical, Inc. will post 4.8 EPS for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.